Botulinum toxin A for the treatment of trigeminal neuralgia and temporomandibular joint dysfunction: a review of the clinical-effectiveness

Sin G, Banks R
Record ID 32011001252
English
Authors' recommendations: There is a lack of high quality evidence pertaining to the assessment of clinical benefit and harm of botulinum toxin A for the treatment of TN and TMD.Included studies suggested that, for TN, botulinum toxin A might be beneficial in pain reduction. None of the included studies reported serious adverse events, although some patients developed transient adverse events. Further research is needed before more definitive conclusions can be drawn. There was no evidence identified for the longer term clinical-effectiveness and safety of botulinum toxin A in the treatment of TN.Included studies reported inconsistent findings for the potential benefit and safety of botulinum toxin A for the treatment of TMD. One systematic review suggested that botulinum toxin A can be effective for managing pain, while another systematic review did not find evidence of botulinum toxin A providing significant differences in pain reduction. Overall, there is some recent, lower-quality evidence to suggest that botulinum toxin A may provide short-term pain relief in some patients with TN and TMD. No recent evidence was found on the longer-term benefit and harm of botulinum toxin A for the treatment of TN and TMD.
Details
Project Status: Completed
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Temporomandibular Joint Dysfunction Syndrome
  • Trigeminal Neuralgia
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.